The Lancet June 19, 2004

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

Stevo Julius, Sverre E Kjeldsen, Michael Weber et al.

Bottom Line

The VALUE trial demonstrated no significant difference in the primary composite endpoint of cardiac morbidity and mortality between valsartan- and amlodipine-based regimens, highlighting that prompt blood pressure reduction itself is the primary driver of cardiovascular protection.

Key Findings

1. The primary composite endpoint of cardiac mortality and morbidity occurred in 10.6% (810 patients, 25.5 per 1000 patient-years) in the valsartan group versus 10.4% (789 patients, 24.7 per 1000 patient-years) in the amlodipine group (HR 1.04, 95% CI 0.94-1.15, p=0.49).

2. Blood pressure was lowered in both arms, but the reduction was significantly more pronounced and rapid with amlodipine (4.0/2.1 mm Hg lower in the amlodipine group at 1 month, and 1.5/1.3 mm Hg lower at 1 year; p<0.001).

3. The valsartan group had a higher risk of fatal and non-fatal myocardial infarction compared to amlodipine (HR 1.19, 95% CI 1.02-1.39), an outcome highly correlated with the unequal blood pressure control early in the trial.

4. Stroke trended higher in the valsartan arm (HR 1.13, 95% CI 0.96-1.33), predominantly reflecting differences during the first 6 months when amlodipine's blood pressure advantage was greatest.

5. Valsartan-based therapy significantly reduced the incidence of new-onset diabetes by 23% compared to amlodipine-based therapy.

Study Design

Design

RCT

Double-Blind

Sample

15,245

Patients

Duration

4.2 yr

Median

Setting

31 countries

Population Patients aged 50 years or older with treated or untreated essential hypertension and at high risk of cardiac events.

Intervention Valsartan-based antihypertensive regimen (initiated at 80 mg, titrated to 160 mg, with subsequent sequential addition of hydrochlorothiazide and other agents to reach a target BP <140/90 mm Hg).

Comparator Amlodipine-based antihypertensive regimen (initiated at 5 mg, titrated to 10 mg, with identical sequential addition of other agents to reach a target BP <140/90 mm Hg).

Outcome Composite of cardiac mortality and morbidity (including sudden cardiac death, fatal/nonfatal myocardial infarction, and heart failure requiring hospital management).

Study Limitations

• The unequal blood pressure reductions between the two arms significantly confounded the direct comparison of the drugs' cardioprotective effects.

• Because blood pressure control was achieved more slowly in the valsartan group, it is difficult to determine whether differences in secondary outcomes (like MI and stroke) were drug-specific effects or purely driven by delayed blood pressure normalization.

• The progressive addition of other antihypertensive agents (like hydrochlorothiazide) to achieve target blood pressures meant the trial compared overall treatment strategies rather than pure monotherapy.

Clinical Significance

The VALUE trial underscored a critical clinical maxim: in high-risk hypertensive patients, the magnitude and speed of blood pressure reduction are paramount for preventing early cardiovascular events (like stroke and MI), often outweighing specific drug class mechanisms. While valsartan did not show BP-independent superiority for cardiovascular outcomes, its metabolic benefit in reducing new-onset diabetes provided a compelling reason for its use in patients with metabolic syndrome.

Historical Context

During the early 2000s, there was intense debate regarding whether blockade of the renin-angiotensin system offered 'pleiotropic' or blood pressure-independent cardioprotection. Following trials like HOPE and LIFE, VALUE was designed to test if valsartan could outcompete the calcium channel blocker amlodipine for exactly the same level of blood pressure control. The trial famously failed to achieve equal blood pressure between the arms, inadvertently cementing the 'lower is better, faster is better' paradigm and sparking years of debate over an apparent 'ARB-MI paradox' that was ultimately attributed to the delayed BP control.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What are the differing mechanisms of action of valsartan and amlodipine, and how do their distinct physiological effects explain why one might theoretically be favored over the other in specific high-risk cardiovascular patients despite the VALUE trial's primary findings?

Key Response

Valsartan is an Angiotensin II Receptor Blocker (ARB) that prevents vasoconstriction and aldosterone release, offering theoretical benefits in heart failure and diabetic nephropathy. Amlodipine is a dihydropyridine calcium channel blocker (CCB) that promotes potent vasodilation, beneficial for angina. Understanding these mechanisms helps students grasp why specific agents are chosen for compelling indications, even if overall cardiovascular mortality outcomes are similar when blood pressure is adequately controlled.

Resident

Based on the VALUE trial's finding that early blood pressure reduction strongly influenced cardiovascular outcomes, how should this impact your approach to titrating antihypertensive medications in a newly diagnosed, high-risk hypertensive patient in the outpatient clinic?

Key Response

The VALUE trial showed that amlodipine lowered blood pressure more quickly than valsartan in the early months, which correlated with early reductions in stroke and myocardial infarction. This teaches residents that achieving blood pressure control promptly is critical in high-risk patients, challenging the traditional 'start low and go slow' approach and supporting the use of early combination therapy or rapid titration.

Fellow

In the VALUE trial, amlodipine achieved BP control more rapidly than valsartan, correlating with early stroke and MI reduction, while valsartan showed a trend toward reduced new-onset heart failure. How do you weigh these competing secondary outcomes when selecting a first-line agent for a patient with both high atherosclerotic risk and subclinical left ventricular dysfunction?

Key Response

Fellows must synthesize complex, sometimes conflicting trial data. While the primary composite outcome showed no difference, the secondary outcomes highlight drug-specific nuances: CCBs provide rapid atherosclerotic protection via potent BP lowering, whereas ARBs offer ventricular remodeling benefits. This requires advanced, personalized risk stratification for complex cardiovascular patients.

Attending

The VALUE trial shifted the paradigm by suggesting 'blood pressure lowering per se' is more important than the specific drug class for overall cardiovascular mortality. How do you use this concept to combat therapeutic inertia and educate junior clinicians who might delay achieving BP targets while overly focusing on finding the 'perfect' evidence-based agent?

Key Response

Attendings need to focus on clinical leadership and systems-based practice. The trial underscores that therapeutic inertia is dangerous; the exact medication matters less than simply getting the blood pressure to goal. This is a crucial teaching point to encourage trainees to titrate or add medications aggressively rather than delaying treatment while debating nuanced drug class benefits.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The early separation of blood pressure between the valsartan and amlodipine arms in the VALUE trial complicated the interpretation of the primary outcomes. What alternative trial designs or post-hoc statistical adjustments, such as marginal structural models or time-varying covariates, could have better isolated the independent drug class effects from the magnitude of BP reduction?

Key Response

The trial design suffered from unequal early BP reduction, which confounded the drug class comparison. PhDs should critically evaluate how time-dependent confounding can be managed, exploring advanced statistical modeling to adjust for continuous BP changes over time to truly isolate the pleiotropic effects of the drugs from their mechanical hypotensive effects.

Journal Editor

As an editor evaluating the VALUE trial manuscript, how do you address the threat to validity posed by the unequal early blood pressure reductions between the two arms, and what specific supplementary analyses would you require from the authors to ensure the conclusion of comparable efficacy is not simply confounded by the BP differential?

Key Response

Editors must ensure rigorous peer review and transparent reporting. The differing BP control rates confound the comparison of drug-specific pleiotropic effects. A rigorous editor would require serial matching of patients with identical BP reductions over time (which the VALUE investigators subsequently attempted) to prove that neither drug has an inherent advantage independent of its blood pressure-lowering efficacy.

Guideline Committee

Given the VALUE trial's evidence that blood pressure control velocity and magnitude eclipse the specific agent used for immediate risk reduction, how should modern hypertension guidelines grade the recommendation for initial single-pill combination therapy versus monotherapy to ensure rapid blood pressure control in high-CV-risk populations?

Key Response

The VALUE trial heavily influenced guidelines by proving that rapid BP lowering saves lives and prevents early strokes/MIs. This historical evidence directly supports modern guidelines, such as the 2017 ACC/AHA and 2018 ESC/ESH updates, which strongly recommend (Class I) starting with two first-line drugs of different classes, preferably in a single-pill combination, for patients with BP significantly above target or those at high cardiovascular risk to accelerate time-to-control.

Clinical Landscape

Noteworthy Related Trials

2002

ALLHAT Trial

n = 33,357 · JAMA

Tested

Amlodipine or Lisinopril

Population

Hypertensive patients aged 55 or older with at least 1 other CHD risk factor

Comparator

Chlorthalidone

Endpoint

Fatal CHD or nonfatal MI

Key result: No difference was found in the primary outcome between the treatments, but chlorthalidone was superior in preventing heart failure compared to amlodipine and stroke compared to lisinopril.

2002

LIFE Trial

n = 9,193 · Lancet

Tested

Losartan-based regimen

Population

Hypertensive patients aged 55-80 years with left ventricular hypertrophy

Comparator

Atenolol-based regimen

Endpoint

Composite of cardiovascular death, stroke, and MI

Key result: Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality, primarily driven by a significant reduction in stroke risk, despite similar blood pressure reductions.

2005

ASCOT-BPLA Trial

n = 19,257 · Lancet

Tested

Amlodipine +/- perindopril

Population

Hypertensive patients with at least 3 other cardiovascular risk factors

Comparator

Atenolol +/- bendroflumethiazide

Endpoint

Non-fatal MI and fatal CHD

Key result: The amlodipine-based regimen significantly reduced all-cause mortality, cardiovascular mortality, and stroke compared to the atenolol-based regimen.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis